Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Urva S, Coskun T, Loghin C, Cui X, Beebe E, O'Farrell L, Briere DA, Benson C, Nauck MA, Haupt A. Urva S, et al. Among authors: haupt a. Diabetes Obes Metab. 2020 Oct;22(10):1886-1891. doi: 10.1111/dom.14110. Epub 2020 Jul 13. Diabetes Obes Metab. 2020. PMID: 32519795 Free PMC article.
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, Robins DA, Haupt A, Duffin KL, Ruotolo G. Wilson JM, et al. Among authors: haupt a. Diabetes Obes Metab. 2022 Jan;24(1):148-153. doi: 10.1111/dom.14553. Epub 2021 Oct 11. Diabetes Obes Metab. 2022. PMID: 34542221 Free PMC article. Clinical Trial.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. Coskun T, et al. Among authors: haupt a. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. Cell Metab. 2022. PMID: 35985340 Free article.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, Haupt A, Benson C. Pratt E, et al. Among authors: haupt a. Diabetes Obes Metab. 2023 Sep;25(9):2642-2649. doi: 10.1111/dom.15150. Epub 2023 Jun 1. Diabetes Obes Metab. 2023. PMID: 37264711 Clinical Trial.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Pratt E, Ma X, Liu R, Robins D, Haupt A, Coskun T, Sloop KW, Benson C. Pratt E, et al. Among authors: haupt a. Diabetes Obes Metab. 2023 Sep;25(9):2634-2641. doi: 10.1111/dom.15184. Epub 2023 Jun 21. Diabetes Obes Metab. 2023. PMID: 37344954 Clinical Trial.
188 results